The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers

Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-02349764
Contributor : Didier Desmaële <>
Submitted on : Tuesday, November 5, 2019 - 6:08:31 PM
Last modification on : Thursday, November 7, 2019 - 1:21:04 AM

Identifiers

Collections

Citation

Philippe Collery, Vijay Veena, Adhikesavan Harikrishnan, Didier Desmaele. The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers. Investigational New Drugs, Springer Verlag, 2019, 37 (5), pp.973-983. ⟨10.1007/s10637-019-00727-1⟩. ⟨hal-02349764⟩

Share

Metrics

Record views

5